Azoles

• 

  Subject Areas on Research

  • Antifungal serum concentration monitoring: an update. 
  • Antifungal treatment in pediatric patients. 
  • Antifungals in Clinical Use and the Pipeline. 
  • Aspergillus fumigatus Cyp51A and Cyp51B Proteins Are Compensatory in Function and Localize Differentially in Response to Antifungals and Cell Wall Inhibitors. 
  • Azole antifungals: 35 years of invasive fungal infection management. 
  • Changing Epidemiology of Invasive Mold Infections in Patients Receiving Azole Prophylaxis. 
  • Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. 
  • Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. 
  • Current options in antifungal pharmacotherapy. 
  • Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. 
  • Erg6 affects membrane composition and virulence of the human fungal pathogen Cryptococcus neoformans. 
  • Fatty acid synthesis is essential for survival of Cryptococcus neoformans and a potential fungicidal target. 
  • Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. 
  • Fungal CYP51 Inhibitors VT-1161 and VT-1129 Exhibit Strong In Vitro Activity against Candida glabrata and C. krusei Isolates Clinically Resistant to Azole and Echinocandin Antifungal Compounds. 
  • Hsp90 governs echinocandin resistance in the pathogenic yeast Candida albicans via calcineurin. 
  • Identification of a key lysine residue in heat shock protein 90 required for azole and echinocandin resistance in Aspergillus fumigatus. 
  • Management of drug and food interactions with azole antifungal agents in transplant recipients. 
  • Molecular approaches to identify novel targets for future development of antifungal agents. 
  • Role of Non-FDG-PET/CT in Head and Neck Cancer. 
  • Structural analyses of Candida albicans sterol 14α-demethylase complexed with azole drugs address the molecular basis of azole-mediated inhibition of fungal sterol biosynthesis. 
  • The Hsp90 co-chaperone Sgt1 governs Candida albicans morphogenesis and drug resistance. 
  • Treatment options for invasive fungal infections. 
• 

  Keywords of People

  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology